Exploring structure-activity relationships of pyrrolyl diketo acid derivatives as non-nucleoside inhibitors of terminal deoxynucleotidyl transferase enzyme
- J Enzyme Inhib Med Chem. 2025 Dec;40(1):2496782. doi: 10.1080/14756366.2025.2496782.
- 1. Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, "Sapienza" Università di Roma, Rome, Italy.
- 2. Institute of Molecular Genetics IGM-CNR, Pavia, Italy.
- 3. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
- 4. Dottorato di Interesse Nazionale in One Health approaches to infectious diseases and life science research, Dipartimento di Sanità Pubblica, Medicina Sperimentale e Forense, Università degli Studi di Pavia, Pavia, Italy.
- 5. Department of Sense Organs, Faculty of Medicine and Odontology, "Sapienza" Università di Roma, Rome, Italy.
- 6. Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
Terminal deoxynucleotidyl transferase (TdT) is overexpressed in some Cancer types, where it drives the mutagenic repair of double strand breaks through non canonical non-homologous end joining pathway. The TdT enzyme belongs to the X family of polymerases, together with the DNA Polymerase λ (pol λ) and β (pol β). However, TdT exclusively displays template-independent nucleotide polymerisation. Pursuing our studies in developing TdT inhibitors, herein we deepened the structure-activity relationships of new structural analogues of our previously identified hit compounds. The diketo hexenoic acid derivatives here analysed showed high selectivity towards TdT and inhibition potencies spanning from the low micromolar range to the nanomolar. Docking studies highlighted the chemical features involved in the TdT binding, well contributing to the rationalisation of the structural requirements needed for the enzymatic inhibition.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: DNA/RNA SynthesisResearch Areas: Cancer